

RESPIRATORY INFECTION

Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus

J B M van Woensel, W M C van Aalderen, W de Weerd, N J G Jansen, J P J van Gestel, D G Markhorst, A J van Vught, A P Bos, J L L Kimpen

Thorax 2003;**58**:383–387

See end of article for authors' affiliations

Correspondence to:
Dr J B M van Woensel,
Academic Medical Center,
Emma Children's Hospital,
Pediatric Intensive Care
Unit G8ZW, P O Box
22660, 1100 DD
Amsterdam, The
Netherlands;
j.b.vanwoensel@amc.uva.nl

Revised version received
11 December 2002
Accepted for publication
6 January 2003

Background: A study was undertaken to evaluate the efficacy of dexamethasone in patients mechanically ventilated for lower respiratory infection caused by respiratory syncytial virus (RSV-LRTI).

Methods: In a multicentre randomised controlled trial patients were randomised to receive either intravenous dexamethasone (0.15 mg/kg 6 hourly for 48 hours) or placebo. End points were the duration of mechanical ventilation, length of stay (LOS) in the pediatric intensive care unit (PICU) and in hospital, and the duration of supplemental oxygen administration.

Results: Thirty seven patients received dexamethasone and 45 received placebo. There was no significant difference in any of the end points between the two groups. In a post hoc analysis patients were stratified into those with mild gas exchange anomalies ($\text{PaO}_2/\text{FiO}_2 > 200$ mm Hg and/or mean airway pressure ≤ 10 cm H_2O , bronchiolitis group) and those with severe gas exchange anomalies ($\text{PaO}_2/\text{FiO}_2 \leq 200$ mm Hg and mean airway pressure > 10 cm H_2O , pneumonia group). In the 39 patients with bronchiolitis the duration of mechanical ventilation was 4.3 days shorter in the dexamethasone group than in the placebo group (4.9 v 9.2 days, 95% CI -7.8 to -0.8 , $p=0.02$) and the duration of supplemental oxygen was 3.6 days shorter (7.7 v 11.3 days, 95% CI -8.0 to -0.1 , $p=0.048$). No differences in end points were found in the pneumonia group.

Conclusions: Dexamethasone had no beneficial effect in patients mechanically ventilated for RSV-LRTI but was found to have a beneficial effect in patients with bronchiolitis.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in young children.¹ Almost all children are infected at least once with RSV before the age of two. About 1% of the children with RSV lower respiratory tract infection (RSV-LRTI) need to be admitted to hospital.² Respiratory failure progresses in 5–8% of them, necessitating mechanical ventilation.^{3–5}

A substantial body of experimental and clinical evidence suggests that the immune response during RSV-LRTI may be deleterious for the host,^{6–8} suggesting that immune modulating drugs such as corticosteroids may be effective. This has been the subject of many trials, most of which found that corticosteroids were not beneficial in patients with mild RSV-LRTI.⁹ However, in a previous trial we found that corticosteroids might be beneficial in patients with severe RSV-LRTI. Oral prednisolone shortened both the duration of mechanical ventilation and the length of stay (LOS) in hospital in a small subgroup of patients who needed mechanical ventilation.¹⁰ To evaluate the role of corticosteroids in this patient group further we performed a multicentre, prospective, double blind, randomised, placebo controlled trial to determine the efficacy of intravenous dexamethasone in patients mechanically ventilated for RSV-LRTI.

METHODS

Study design

The study was conducted in five pediatric intensive care units (PICU) in the Netherlands. All patients younger than 24 months on mechanical ventilation for RSV-LRTI were eligible for enrolment. The presence of RSV infection was confirmed by direct immunofluorescence assay (Imagen, Dako, Denmark) of a nasopharyngeal aspirate during the first 24 hours after hospital admission. The decision to start mechanical

ventilation was taken in the referring hospital or by the attending intensive care physician. Patients were only included after parents gave their written informed consent. Those who had used systemic or inhaled corticosteroids within the 2 months before admission were excluded. The medical ethical review board of each participating centre approved the study.

Patients were ventilated with a Servo 300A (Siemens, Munich, Germany), or an Evita 4 (Dräger, Lübeck, Germany) ventilator. Ventilation setting management, weaning policy, and the decision to stop ventilation were left to the attending PICU team according to local policies. Ventilation strategies and sedation protocols did not differ widely in the participating PICUs. Clinical decisions were made by each patient's physicians independent of the study protocol. In order to minimise the potential bias caused by differences in patient management in the different centres, randomisation was stratified for each participating centre. Patients were allocated to dexamethasone or placebo by computerised block randomisation in groups of 10, centrally performed by an independent pharmacist. Each participating centre received a randomisation list and the trial medication preparation protocol. The trial medication was prepared in advance in the pharmacy where the concealed randomisation list was kept until the study was completed. Each enrolled patient received the trial medication with the next number in sequence. The trial medication was intravenous dexamethasone (0.15 mg/kg 6 hourly for 48 hours) or placebo and had to be started within 24 hours after the start of mechanical ventilation.

End points for the efficacy analysis were the duration of mechanical ventilation, LOS in the PICU and in the hospital, and duration of supplemental oxygen.

The mean blood pressure and glucosuria tests were recorded daily on the first 5 days of admission. To monitor the duration




Figure 1 Enrolment of patients to trial.

of viral shedding, RSV immunofluorescence assay of nasopharyngeal aspirate was repeated on days 2, 3, 7, 10 and 14 while the patient was an inpatient. If two consecutive assays were negative the viral shedding was considered to be negative.

Statistical analysis

The previously found difference of 1.5 days in mechanical ventilation was considered to be clinically relevant; in order for this difference to be detected, 60 patients (30 in each arm) would be needed ($\alpha=0.05$, $\beta=80\%$).

Statistical analysis was performed with SPSS for Windows, version 10.1 (SPSS Inc). The Student's *t* test was used to com-

pare group means for normally distributed data; otherwise the Mann-Whitney U test was applied. Proportions were compared by the χ^2 test. A two sided *p* value of <0.05 was considered statistically significant. Data were analysed according to the intention to treat principle. Data in the tables are given as mean (SE) unless otherwise stated.

RESULTS

Eligible patients

From December 1997 to March 2001 155 patients met the inclusion criteria and were eligible for enrolment. Seventy patients were not randomised for reasons shown in fig 1. Of

Table 1 Characteristics of patients on admission in the PICU according to treatment group

	Dexamethasone (n=37)	Placebo (n=45)	p value
Male	30	27	0.054
Age (weeks)	5.9 (0.9)	9.8 (1.6)	0.04
Risk group	12	17	0.65
Premature*	10	12	1.0
CLD	1	2	1.0
CHD	1	1	1.0
Other†	0	2	0.5
Family history of asthma‡	9	11	1.0
Duration of symptoms (days)	3.3 (0.3)	3.6 (0.3)	1.0
Apnoea	5	9	0.55
Wheezing	16	21	0.83
Admission weight (kg)	4.1 (0.2)	4.3 (0.2)	0.32
Median (IQR) PRISM score	9 (7–12)	10 (7–12)	0.97
SIMV/PC	28	29	0.34
Median (IQR) PIP (cm H ₂ O)§	24 (20–26)	24 (22–26)	0.72
Median (IQR) PEEP (cm H ₂ O)§	4 (4–5)	4 (4–5)	0.70
PaO ₂ /FiO ₂ ratio (mm Hg)	180 (9)	173 (11)	0.77
Time elapsed between start mechanical ventilation and start trial medication (h)	15 (1.2)	14 (1.3)	0.53

CLD=chronic lung disease; CHD=congenital heart disease; SIMV/PC=synchronised intermittent mandatory ventilation, pressure controlled; PIP=positive inspiratory pressure; PEEP=positive end expiratory pressure.

*Prematurity was defined as a gestational duration of less than 36 weeks.

†One patient with cardiomyopathy, one patient with lung hypoplasia.

‡Mother, father or sibling with asthma.

§Only in patients with SIMV/PC ventilation.

Table 2 Mean (SE) duration of mechanical ventilation, length of stay (LOS) in the paediatric intensive care unit (PICU) and hospital, and duration of supplemental oxygen in the two treatment groups

	Dexamethasone (n=37)	Placebo (n=45)	95% CI for difference	p value
Duration of mechanical ventilation (days)	6.9 (0.7)	8.5 (0.9)	-3.8 to 0.8	0.19
LOS in PICU (days)	9.1 (0.9)	9.9 (0.9)	-3.4 to 1.8	0.53
LOS in hospital (days)	15.9 (1.5)	14.9 (1.2)	-2.8 to 4.7	0.52
Duration of supplemental oxygen (days)	10.0 (1.2)	10.9 (1.0)	-3.9 to 2.1	0.55

the 85 patients who were enrolled, 39 were randomised to receive dexamethasone and 46 to receive placebo. After enrolment three patients were withdrawn, one (dexamethasone group) because she died 4 days after admission due to severe cerebral oedema in combination with refractory seizures existing already before inclusion, and two because their medication vials (one containing dexamethasone and the other placebo) were accidentally interchanged. Eighty two patients therefore completed the trial, 37 of whom received dexamethasone and 45 placebo.

Baseline characteristics

The baseline characteristics of the study participants are shown in table 1. The proportion of males was higher in the dexamethasone group than in the placebo group and the dexamethasone group was significantly younger than the placebo group. There were no other differences in baseline characteristics between the two treatment groups.

Outcome

The mean duration of mechanical ventilation in the dexamethasone group was 1.6 days shorter than in the placebo group; this difference was not statistically significant (table 2). There was no difference in either the mean LOS in the PICU and in the hospital or the mean duration of supplemental oxygen between the two treatment groups. The results were not different after correction for sex or age (data not shown). Five patients (two in the dexamethasone group and three in the placebo group) needed to be re-intubated because of upper airway obstruction following intubation.

During the course of the trial Tasker *et al* published a study in which they reported that mechanically ventilated patients with RSV-LRTI may present with two patterns of disease which can be distinguished on the basis of early respiratory

parameters.⁵ In order to determine whether the effect of dexamethasone was dependent on these clinical patterns we performed a post hoc subgroup analysis. Patients were stratified according to the P_{aO_2}/F_{iO_2} ratio and the mean airway pressure (MAP) on the day of admission, analogous to the criteria described by Tasker *et al*.⁵ Arterial blood gas analysis data were available for 80 patients during the first 24 hours of admission (in case more blood gas analyses were available the worst P_{aO_2}/F_{iO_2} was chosen). These patients were stratified into a bronchiolitis group (mild gas exchange anomalies: $P_{aO_2}/F_{iO_2} > 200$ mm Hg and/or $MAP \leq 10$ cm H₂O, n=39) and a pneumonia group (severe gas exchange anomalies: $P_{aO_2}/F_{iO_2} \leq 200$ mm Hg and $MAP > 10$ cm H₂O, n=41). There were no differences in baseline characteristics between the dexamethasone and placebo treated patients within the bronchiolitis and pneumonia groups. The results of the end point analyses in these subgroups are shown in table 3. In the bronchiolitis group the mean duration of mechanical ventilation in the patients who received dexamethasone was 4.3 days shorter than in those who received placebo (4.9 v 9.2 days, 95% CI -7.8 to -0.8 days, p=0.02). The mean LOS in the PICU was 2.4 days shorter in the dexamethasone group than in the placebo group but this difference was not statistically significant (7.9 v 10.3 days, 95% CI -6.8 to 2.0, p=0.28). However, in the mild group three patients (two of whom received dexamethasone and one placebo) needed to be re-intubated because of upper airway obstruction following intubation. If these three patients were excluded from the analysis there was a significant difference of 3.9 days in mean LOS in the PICU (6.6 v 10.5 days, 95% CI -7.6 to -0.2, p=0.039). The mean LOS in hospital and the mean duration of supplemental oxygen were also shorter in the dexamethasone group than in the placebo group, but only the difference in duration of supplemental oxygen reached statistical significance. In the pneumonia group there was no significant

Table 3 Mean (SE) duration of mechanical ventilation, length of stay (LOS) in the paediatric intensive care unit (PICU) and hospital, and supplemental oxygen in days in the two treatment groups according to subgroup analysis*

	Dexamethasone	Placebo	95% CI for difference	p value
Bronchiolitis group†				
n	18	21		
Duration of mechanical ventilation	4.9 (0.5)	9.2 (1.6)	-7.8 to -0.8	0.02
LOS PICU	7.9 (1.4)	10.3 (1.6)	-6.8 to 2.0	0.28
LOS hospital	14.9 (2.0)	16.0 (1.9)	-6.7 to 4.5	0.11
Duration of supplemental oxygen	7.7 (0.9)	11.3 (1.6)	-8.0 to -0.1	0.048
Pneumonia group‡				
n	19	22		
Duration of mechanical ventilation	8.9 (1.1)	8.1 (1.0)	-2.2 to 3.6	0.61
LOS PICU	10.1 (1.1)	9.9 (1.2)	-3.1 to 3.5	0.90
LOS hospital	16.7 (2.2)	14.1 (1.5)	-2.8 to 8.0	0.34
Duration of supplemental oxygen	12.1 (1.9)	10.4 (1.0)	-2.7 to 6.1	0.50

*Arterial blood gas analysis was available for 37 patients in the dexamethasone group and 43 patients in the placebo group.

†Bronchiolitis group: patients with $P_{aO_2}/F_{iO_2} > 200$ mm Hg and/or mean airway pressure ≤ 10 cm H₂O.

‡Pneumonia group: patients with $P_{aO_2}/F_{iO_2} \leq 200$ mm Hg and $MAP > 10$ cm H₂O.

Table 4 Concomitant treatment according to treatment group

	Dexamethasone (n=37)	Placebo (n=46)	p value
Antibiotic treatment*			
Started before or on admission	24	32	0.8
Started >1 day after admission	10	12	1.0
Bronchodilator therapy during admission	19	27	0.65
Mean (SE) duration of bronchodilator treatment (days)	5.3 (0.6)	5.3 (0.7)	0.98
Additional corticosteroid therapy	2	1	–
Paralysing agents during admission	9	15	0.47
Mean (SE) duration of paralysing agents (days)	3.8 (0.7)	4.5 (0.8)	0.54

* Amoxicillin (with or without clavulanic acid) or a macrolide were the most frequently prescribed antibiotics: 92% v 75% in the dexamethasone and placebo groups respectively, $p=0.36$.

difference in any of the end points between the dexamethasone and placebo treated patients.

Concomitant treatment

There were no differences in concomitant treatment with antibiotics, bronchodilators or paralysing agents between the two treatment groups (table 4). None of the patients received palivizumab before admission or ribavirin during admission. Three patients received corticosteroids after randomisation; two (one from each treatment group) were started after 8 days with the aim of getting them off the ventilator earlier and one in the dexamethasone group was started on corticosteroids after 2 days because of suspicion of adrenal insufficiency.

Side effects

Mean blood pressure both before the start of trial medication (59 v 58 mm Hg in the dexamethasone and placebo group, respectively, $p=0.72$) and during the first 5 days of admission (42 mm Hg in both groups, $p=0.36$) did not differ between the two treatment groups. In one patient (dexamethasone group) malignant hypertension developed 3 days after start of the trial medication which later proved to be caused by a renal vein thrombosis. During the first 5 days of admission glucosuria was found on 7 of the 146 days when urine was checked in the dexamethasone group and on 5 of the 163 days when urine was checked in the placebo group ($p=0.56$).

During the first 2 weeks of admission at least two RSV immunofluorescence assays were repeated in 58 patients (23 in the dexamethasone group and 35 in the placebo group). In six patients in the dexamethasone group and in nine in the placebo group the test became negative ($p=0.60$).

DISCUSSION

The results of this trial show that dexamethasone does not lead to a shorter duration of mechanical ventilation in patients with RSV-LRTI. Although dexamethasone shortened the duration of mechanical ventilation by more than 1 day in the whole study cohort, this difference did not reach statistical significance. Our results confirm a very recently published trial that also evaluated the efficacy of dexamethasone in mechanically ventilated patients with RSV-LRTI. However, this trial was primarily designed to evaluate differences in virus quantity and the authors stated that it was underpowered to detect differences of <50% between the two groups.¹¹

RSV induced respiratory insufficiency may present with two different patterns. The first pattern, classically referred to as bronchiolitis, is characterised predominantly by obstruction of the airways while the second pattern, classically referred to as pneumonia, is characterised by a predominantly restrictive parenchymal lung disease with alveolar consolidation on the chest radiograph and has many features in common with acute respiratory distress syndrome (ARDS).¹² Tasker *et al* have shown that it is possible to identify the group with four quadrant alveolar consolidation on the chest radiograph (compat-

ible with RSV pneumonia) by using the alveolar arterial oxygen gradient (AaDo₂) and MAP during the first 24 hours of admission to the PICU. They found that AaDo₂ of ≥ 400 mm Hg and MAP of > 10 cm H₂O had a very high positive and negative predictive value for a four quadrant alveolar consolidation. In addition, they found that the LOS of this group in the PICU is much longer than for those with mild gas exchange anomalies on admission and suggested that trials evaluating treatment of mechanically ventilated patients with RSV-LRTI should stratify for these two disease patterns.³ By combining the results of lung function studies in patients with RSV-LRTI with the results of the study by Tasker *et al*, Newth concluded that patients with mild gas anomalies may reflect a mainly obstructive pulmonary function pattern (i.e. bronchiolitis) while severe gas exchange anomalies are consistent with a severe restrictive pulmonary function pattern (i.e. pneumonia).^{12–14} In addition, Newth showed that the AaDo₂ value of ≥ 400 mm Hg that was used corresponds to a Pao₂/Fio₂ ratio of approximately ≤ 200 mm Hg which is used to define ARDS.^{13–15} By applying a cut off value of 200 mm Hg for the Pao₂/Fio₂ ratio and of 10 cm H₂O for the MAP to differentiate between patients with RSV bronchiolitis and those with pneumonia (who did not fulfil both criteria), we found a marked difference in the efficacy of dexamethasone between these subgroups. Dexamethasone reduced mechanical ventilation by more than 4 days and LOS in the PICU by more than 2 days in the bronchiolitis group. In addition, the LOS in hospital and the duration of supplemental oxygen were reduced by dexamethasone, only the latter end point being statistically significant.

For several reasons our results should be interpreted with caution. Firstly, the efficacy of dexamethasone in patients with RSV bronchiolitis was demonstrated by a post hoc analysis. This only generates the hypothesis that corticosteroids may be beneficial in patients with bronchiolitis and needs to be confirmed in a prospectively conducted randomised trial. Secondly, Tasker *et al* found an important difference in LOS in the PICU between patients with mild gas exchange anomalies and those with severe gas exchange anomalies. By applying their criteria we would have expected to find a similar difference between these two subgroups in the placebo treated patients but this was not the case, which underscores the need for further studies on this topic.

The efficacy of corticosteroids in patients with RSV-LRTI has been studied for decades with conflicting results.^{10–16–29} Although some found a beneficial effect,^{10–16–19–21–22} most well designed randomised controlled trials did not show that corticosteroids were beneficial.^{23–29} Like other workers, in an earlier trial we were unable to show that oral prednisolone was beneficial in patients with mild RSV-LRTI.¹⁰ However, prednisolone shortened the duration of mechanical ventilation and the LOS in hospital in a small group of patients on mechanical ventilation. The results reported here support our previous findings that corticosteroids are beneficial in a

subgroup of patients with RSV bronchiolitis. Further research is needed to identify more precisely patients in the PICU with RSV-LRTI in whom corticosteroids are potentially beneficial.

Since no treatment is available for RSV-LRTI, our findings may indicate a step forward in the search for effective treatment. This may have an important socioeconomic impact since hospital admissions for bronchiolitis have increased substantially over the last decade and it is estimated that, in the USA, more than 120 000 children are admitted annually with RSV-LRTI.³⁰

In our previous trial we used oral prednisolone in a dose of 1 mg/kg/day for 7 days. Because the beneficial effect of prednisolone was mainly seen in the first 3 days, in the current trial a shorter and higher dose of intravenous corticosteroids was used. On the basis of the dose used in patients with laryngitis subglottica and meningitis,^{31 32} the dose of dexamethasone chosen was 0.6 mg/kg/day (equivalent to 6 mg/kg/day prednisolone). The parenteral route was chosen because mechanically ventilated patients were studied.

The beneficial effects of intravenous dexamethasone should outweigh the potential side effects. No significant side effects were found in the present study, which is in accordance with what is known about short courses of steroid treatment.³³

In conclusion, dexamethasone was not found to be beneficial in patients needing mechanical ventilation for RSV-LRTI. However, post hoc subgroup analysis suggested a beneficial effect of dexamethasone in a subgroup of patients with RSV bronchiolitis. Although our findings indicate a significant improvement in the therapeutic possibilities for patients with RSV bronchiolitis who need mechanical ventilation, this observation can only be considered hypothetical and should be tested in a prospective randomised controlled trial.

ACKNOWLEDGEMENTS

We thank the trial pharmacists and medical staff and nurses of all participating centres for their help with preparing the trial medication and including patients and completing the trial respectively, and the Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam for their statistical advice and support.

Authors' affiliations

J B M van Woensel, W M C van Aalderen, A P Bos, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands
N J G Jansen, J P J van Gestel, A J van Vught, J L L Kimpen, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands
W de Weerd, Beatrix Children's Hospital, Academic Hospital Groningen, The Netherlands
D G Markhorst, VU Medical Center, Amsterdam, The Netherlands
N J G Jansen, University Hospital, Maastricht, The Netherlands

REFERENCES

- 1 Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. *N Engl J Med* 1973;**288**:498–505.
- 2 Everard ML, Milner AD. The respiratory syncytial virus and its role in acute bronchiolitis. *Eur J Pediatr* 1992;**151**:638–51.
- 3 Helfaer MA, Nichols DG, Rogers MC. Lower airway disease: bronchiolitis and asthma. In: Nichols DG, Rogers MC, eds. *Textbook of pediatric intensive care*. Baltimore: Williams and Wilkins, 1996:127–64.
- 4 Stretton M, Ajizian SJ, Mitchell I, et al. Intensive care course and outcome of patients infected with respiratory syncytial virus. *Pediatr Pulmonol* 1992;**13**:143–50.

- 5 Tasker RC, Gordon I, Kiff K. Time course of severe respiratory syncytial virus infection in mechanically ventilated patients. *Acta Paediatr* 2000;**89**:938–41.
- 6 Kimpen JLL, Heymans HSA. Respiratory syncytial virus: immunity and immune injury. *Immunol Infect Dis* 1993;**3**:281–8.
- 7 Openshaw PJ. Immunopathological mechanisms in respiratory syncytial virus disease. *Springer Semin Immunopathol* 1995;**17**:187–201.
- 8 Graham BS, Bunton LA, Rowland J, et al. Respiratory syncytial virus infection in anti-mu-treated mice. *J Virol* 1991;**65**:4936–42.
- 9 van Woensel JBM, Kimpen JLL. Therapy for respiratory tract infection caused by respiratory syncytial virus. *Eur J Pediatr* 2000;**159**:391–8.
- 10 van Woensel JBM, Wolfs TFW, van Aalderen WMC, et al. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. *Thorax* 1997;**52**:634–7.
- 11 Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. *J Infect Dis* 2002;**185**:1222–8.
- 12 Hammer J, Numa A, Newth CJL. Acute respiratory distress syndrome caused by respiratory syncytial virus. *Pediatr Pulmonol* 1997;**23**:176–83.
- 13 Newth CJ. Time course of severe respiratory syncytial virus infection in mechanically ventilated infants. *Acta Paediatr* 2000;**89**:893–5.
- 14 Hammer J, Numa A, Newth CJL. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. *J Pediatr* 1995;**127**:485–90.
- 15 Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS. *Am J Respir Crit Care Med* 1994;**149**:818–24.
- 16 Oski FA, Salitsky S, Barness LA. Steroid therapy in bronchiolitis: a double-blind study. *Am J Dis Child* 1961;**102**:759.
- 17 Dabbous IA, Tkachyk JS, Stamm SJ. A double blind study on the effects of corticosteroids in the treatment of bronchiolitis. *Pediatrics* 1966;**37**:477–84.
- 18 Tal A, Bavliski C, Yohai D, et al. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. *Pediatrics* 1983;**71**:13–8.
- 19 Goebel J, Estrada B, Quinonez J, et al. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. *Clin Pediatr* 2000;**39**:213–20.
- 20 Dennis JL. Steroids in the treatment of obstructive bronchiolitis: a double-blind study. *Southern Med J* 1963;**56**:1436.
- 21 Sussman S, Grossman M, Magoffin R, et al. Dexamethasone in obstructive respiratory tract infection in children. A controlled study. *Pediatrics* 1964;**34**:851.
- 22 Connolly JH, Field CMB, Glasgow JFT, et al. A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus. *Acta Paediatr Scand* 1969;**58**:116–20.
- 23 Leer JA, Green JL, Heimlich EM, et al. Corticosteroid treatment in bronchiolitis. *Am J Dis Child* 1969;**117**:495–503.
- 24 Springer C, Bar-Yishay E, Uwayyed K, et al. Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. *Pediatr Pulmonol* 1990;**9**:181–5.
- 25 Roosevelt G, Sheehan K, Grupp-Phelan J, et al. Dexamethasone in bronchiolitis: a randomised controlled trial. *Lancet* 1996;**348**:292–5.
- 26 Klassen TP, Sutcliffe T, Watters LK, et al. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. *J Pediatr* 1997;**130**:191–6.
- 27 De Boeck K, Van der Aa N, Van Lierde S, et al. Respiratory syncytial virus bronchiolitis. A double blind dexamethasone efficacy study. *J Pediatr* 1997;**131**:919–21.
- 28 Berger I, Argaman Z, Schwartz SB, et al. Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up. *Pediatr Pulmonol* 1998;**26**:162–6.
- 29 Bulow SM, Nir M, Levin E, et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 patients. *Pediatrics* 1999;**104**:e77.
- 30 Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980–1996. *JAMA* 1999;**282**:1440–6.
- 31 Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. *Pediatr Infect Dis J* 1998;**17**:827–34.
- 32 Wood AJJ, Quargliarello VJ, Scheld WM. Treatment of bacterial meningitis. *N Engl J Med* 1997;**336**:708–16.
- 33 Orth DN, Kovacs WJ, DeBold CR. The adrenal cortex. In: Wilson JD, Foster DW, Kronenberg HM et al, eds. *Williams' textbook of endocrinology*. Philadelphia: Saunders, 1998: 517–664.